Medizentrum Essen Borbeck — Clinical Trial Site

45 Registered trials

11 Currently recruiting

Organisation

Medizentrum Essen Borbeck

Location

Essen, Germany

Identifier

ORG-100042806

Address

Hülsmannstraße 6, Borbeck, 45355, Germany

Departments

-
#3445
3455
7409 Internal and Sports Medicine
Allergology
DE008: Internal and Sports Medicine
Dres. Preuße/Sanuri/Schaefer
General Physician
Internal Medicine
Medizentrum
Medizentrum Essen Borbeck
Medizentrum Essen Borbeck,
Medizentrum Essen-Borbeck
Medizinzentrum Essen Borbeck
n.a.
N/A
NA
Not applicable
Studienzentrum

Clinical trials at this site (45)

Search interface

A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges… Not authorised

2025-521764-35-00 acute pharyngitis 5
Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending

2025-523486-17-00 Obesity 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Grass pollen induced allergic rhinitis or rhinoconjunct 10 2026-06-01
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Obesity 5 2026-04-13
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with li… Recruiting

2024-512104-19-00 Irritable Bowel Syndrome 6 2019-11-19
A Phase 1/2 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Ended

2024-519005-35-00 Type 2 Diabetes Mellitus 7 2026-03-09
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes 5 2025-08-15
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYND 4 2025-03-19
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Obesity 5 2024-10-22
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23